DK2121746T3 - Potente og selektive mediatorer af kolesterolefflux - Google Patents
Potente og selektive mediatorer af kolesteroleffluxInfo
- Publication number
- DK2121746T3 DK2121746T3 DK07874411.7T DK07874411T DK2121746T3 DK 2121746 T3 DK2121746 T3 DK 2121746T3 DK 07874411 T DK07874411 T DK 07874411T DK 2121746 T3 DK2121746 T3 DK 2121746T3
- Authority
- DK
- Denmark
- Prior art keywords
- cholesterol efflux
- potent
- polypeptides
- apo
- parallels
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 230000003389 potentiating effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000007592 Apolipoproteins Human genes 0.000 abstract 2
- 108010071619 Apolipoproteins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87490906P | 2006-12-13 | 2006-12-13 | |
| PCT/US2007/087477 WO2008115303A2 (en) | 2006-12-13 | 2007-12-13 | Potent and selective mediators of cholesterol efflux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2121746T3 true DK2121746T3 (da) | 2012-03-05 |
Family
ID=39766652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07874411.7T DK2121746T3 (da) | 2006-12-13 | 2007-12-13 | Potente og selektive mediatorer af kolesterolefflux |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8987192B2 (https=) |
| EP (1) | EP2121746B1 (https=) |
| JP (1) | JP2010513311A (https=) |
| CN (1) | CN101675072A (https=) |
| AT (1) | ATE533783T1 (https=) |
| AU (1) | AU2007349237B2 (https=) |
| CA (1) | CA2672131C (https=) |
| DK (1) | DK2121746T3 (https=) |
| ES (1) | ES2377329T3 (https=) |
| WO (1) | WO2008115303A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155366A2 (en) | 2008-06-18 | 2009-12-23 | The Regents Of The University Of California | Improved peptide mediators of cholesterol efflux |
| WO2011079214A1 (en) * | 2009-12-23 | 2011-06-30 | Artery Therapeutics, Inc., | Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases |
| US20130123173A1 (en) * | 2010-04-28 | 2013-05-16 | The Regents Of The University Of California | Creation of oxidation-resistant hdl mimetic peptides |
| JP6549554B2 (ja) | 2013-03-15 | 2019-07-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | コレステロール流出を刺激する、減少した毒性を有するペプチド |
| WO2016044177A1 (en) * | 2014-09-17 | 2016-03-24 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
| CN112511569B (zh) * | 2021-02-07 | 2021-05-11 | 杭州筋斗腾云科技有限公司 | 网络资源访问请求的处理方法、系统及计算机设备 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60035163T2 (de) | 1999-03-15 | 2008-02-21 | University Of British Columbia, Vancouver | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
| AU5323301A (en) * | 2000-04-06 | 2001-10-23 | Kos Pharma Inc | Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| CA2549529A1 (en) | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| KR101185609B1 (ko) * | 2004-07-16 | 2012-09-24 | 트러스티즈 오브 터프츠 칼리지 | 아포리포단백질 ａ１ 미메틱 및 이의 용도 |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
-
2007
- 2007-12-13 CA CA2672131A patent/CA2672131C/en not_active Expired - Fee Related
- 2007-12-13 AU AU2007349237A patent/AU2007349237B2/en not_active Ceased
- 2007-12-13 WO PCT/US2007/087477 patent/WO2008115303A2/en not_active Ceased
- 2007-12-13 ES ES07874411T patent/ES2377329T3/es active Active
- 2007-12-13 EP EP07874411A patent/EP2121746B1/en not_active Not-in-force
- 2007-12-13 AT AT07874411T patent/ATE533783T1/de active
- 2007-12-13 CN CN200780046286A patent/CN101675072A/zh active Pending
- 2007-12-13 DK DK07874411.7T patent/DK2121746T3/da active
- 2007-12-13 US US12/519,116 patent/US8987192B2/en active Active
- 2007-12-13 JP JP2009541599A patent/JP2010513311A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1138292A1 (en) | 2010-08-20 |
| US20120329703A1 (en) | 2012-12-27 |
| WO2008115303A3 (en) | 2008-12-24 |
| EP2121746A2 (en) | 2009-11-25 |
| ATE533783T1 (de) | 2011-12-15 |
| US8987192B2 (en) | 2015-03-24 |
| AU2007349237A1 (en) | 2008-09-25 |
| CA2672131C (en) | 2016-06-07 |
| EP2121746B1 (en) | 2011-11-16 |
| AU2007349237B2 (en) | 2014-01-23 |
| WO2008115303A2 (en) | 2008-09-25 |
| CN101675072A (zh) | 2010-03-17 |
| JP2010513311A (ja) | 2010-04-30 |
| CA2672131A1 (en) | 2008-09-25 |
| ES2377329T3 (es) | 2012-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009155366A3 (en) | Improved peptide mediators of cholesterol efflux | |
| DK2121746T3 (da) | Potente og selektive mediatorer af kolesterolefflux | |
| NO20073981L (no) | Criptobindende molekyler | |
| NO20080246L (no) | Anti-IGF1R-antistofformuleringer | |
| WO2007044763A3 (en) | System and method for detecting fraudulent transactions | |
| DE602006017579D1 (de) | Klebstoff für optischen film sowie von dem klebstoff gebrauch machendes klebevlies und optisches glied | |
| WO2005094440A3 (en) | Nanofiber surface based capacitors | |
| WO2006045096A3 (en) | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | |
| ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
| DK1836169T3 (da) | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser | |
| WO2007135571A3 (en) | Blood group antigens of different types for diagnostic and therapeutic applications | |
| DK1420759T3 (da) | Farmaceutiske sammensætninger til behandling af astma | |
| WO2008115469A3 (en) | Role of hedgehog signaling in atherosclerosis and cardiovascular disease | |
| WO2004009062A3 (en) | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | |
| WO2006096489A3 (en) | Anti-m-csf antibody compositions having reduced levels of endotoxin | |
| WO2008045406A3 (en) | COMPOUNDS, SCREENINGS, AND METHODS OF TREATMENT | |
| WO2005118511A3 (en) | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | |
| DK1746101T4 (da) | Fremgangsmåde til fremstilling af 3-oxo-pregn-4-en-21,17-carbolactoner ved metalfri oxidation af 17-(3-hydroxypropyl)-3,17-dihydroxyandrostaner | |
| TW200615399A (en) | Coating material for coating platinum material, platinum material having such coating material, and glass making apparatus | |
| WO2006022955A3 (en) | Topoisomerase inhibitors | |
| WO2007111982A3 (en) | Methods for treating cognitive and other disorders | |
| DK1905452T3 (da) | Middel til forebyggelse eller behandling af glaukom | |
| BRPI0622083A2 (pt) | Método e aparelho destinados à fabricação de substratos purificados ou substratos puros que são adicionalmente processados. | |
| EP1824498A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PROLIFERATIVE CELL DISEASES | |
| WO2007059341A3 (en) | Pyrazolothiazole protein kinase modulators |